title: Liquid versus foam sclerotherapy.
abstract: OBJECTIVE
  A systematic review to compare efficacy and safety of foam (F) sclerotherapy versus liquid (L) sclerotherapy for primary varicose veins of the lower limbs.
  
  
  METHODS
  Systematic searches of electronic databases were conducted in April 2009 to identify relevant published studies. Database searches were augmented with abstracts from conference proceedings and electronic and hand searching of journals not consistently indexed in the major databases.
  
  
  RESULTS
  For treatment of saphenous veins, six trials (four randomized controlled trials) were considered. Despite containing much less sclerosing agent, F was markedly more effective compared with L, the difference being put at between 20% and 50%. Four studies were included in a meta-analysis showing efficacy of F at 76.8% (95% confidence interval [CI] 71-82) versus L at 39.5% (95% CI 33-46), chi(2) = 60.9740; P < or = 0.0001. For reticular veins and telangiectases, only two comparative trials were found and do not at present provide any conclusive evidence to support the superiority of efficacy of one form over the other. Statistically, the side-effects reported in all the available comparative trials do not differ between F and L forms, even if visual disturbances seem to be more common with F.
  
  
  CONCLUSIONS
  In the treatment of varices of the lower limbs, F shows much greater efficacy compared to L. Concerning the side effects, no statistical significant differences were found between L and F.
authors: Department of Vascular Medicine, Saint Martin Private Hospital, 18 rue des Roquemonts, 14050 Caen, France. claudine@desnos.eu
authors: C
authors: C
authors: Hamel-Desnos
authors: F-A
authors: FA
authors: Allaert
mesh_terms: D004304:Dosage Forms; D006801:Humans; D015201:Meta-Analysis as Topic; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D012501:Saphenous Vein; D012597:Sclerosing Solutions / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015911:Sclerotherapy / Q000009:adverse effects / Q000379:methods*; D012996:Solutions; D013684:Telangiectasis / Q000628:therapy*; D018084:Ultrasonography, Interventional; D014648:Varicose Veins / Q000628:therapy*; D014689:Venous Insufficiency / Q000628:therapy*; D014786:Vision Disorders / Q000209:etiology
chemical_list: D004304:Dosage Forms; D012597:Sclerosing Solutions; D012996:Solutions